Effect of niacin on lipids and glucose in patients with type 2 diabetes: A meta-analysis of randomized, controlled clinical trials

Published:September 27, 2014DOI:https://doi.org/10.1016/j.clnu.2014.09.019

      Summary

      Background & aims

      This study aims to conduct a meta-analysis to evaluate the effects of niacin on serum lipids and glucose in patients with type 2 diabetes mellitus (T2DM).

      Methods

      A comprehensive literature search in Medline, Scopus, AMED, Cochrane and Clinical trial registry databases was performed to identify randomized controlled trials investigating the effect of niacin on serum HDL cholesterol (HDL-c), LDL cholesterol (LDL-c), triglycerides (TG) and fasting plasma glucose (FPG). Pooled effects were measured by weighted mean difference (WMD) using fixed-effects or random-effects models. Quality assessment, and subgroup, meta-regression and sensitivity analyses were conducted using standard methods. Inter-study heterogeneity was assessed and quantified.

      Results

      The estimated pooled mean changes (95% confidence interval) with niacin were 0.27 (95% CI: 0.24 to 0.30; P < 0.001) mmol/L for HDL-c, −0.250 (95% CI: −0.47 to −0.03; P < 0.05) mmol/L for LDL-c and −0.39 (95% CI: −0.43 to −0.34; P < 0.001) mmol/L for TG compared with controls. There was a significant heterogeneity for the impact of niacin on LDL-c and FPG. Subgroup analyses revealed a significant increase in FPG 0.085 (95% CI: 0.029 to 0.141; P < 0.05) mmol/L compared with controls in patients with long term treatment. Our analysis also showed the absence of publication bias and any dose-response relations between niacin and effect size.

      Conclusions

      Analysis of the results showed that niacin alone or in combination significantly improved lipid abnormalities in patients with TDM, but requires monitoring of glucose in long term treatment.

      Keywords

      Abbreviations:

      CI (confidence interval), FPG (fasting plasma glucose), HDL-c (HDL cholesterol), LDL-c (LDL cholesterol), RCT (randomised control trial), T2DM (type 2 diabetes mellitus), TG (triglycerides), WMD (weighted mean difference)
      To read this article in full you will need to make a payment
      Subscribe to Clinical Nutrition
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Basevi V.
        • Di Mario S.
        • Morciano C.
        • Nonino F.
        • Magrini N.
        Comment on: American Diabetes Association. Standards of medical care in diabetes–2011.
        Diabetes Care. 2011; 34 (Diabetes Care. 2011, 34, e53; author reply e54): S11-S61
        • Athyros V.G.
        • Tziomalos K.
        • Karagiannis A.
        • Mikhailidis D.P.
        Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.
        Open Cardiovasc Med J. 2011; 5: 24-34
        • Guyton J.R.
        • Goldberg A.C.
        • Kreisberg R.A.
        • Sprecher D.L.
        • Superko H.R.
        • O'Connor C.M.
        Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.
        Am J Cardiol. 1998; 82: 737-743
        • Malik S.
        • Kashyap M.L.
        Niacin, lipids, and heart disease.
        Curr Cardiol Rep. 2003; 5: 470-476
        • Taylor A.J.
        • Sullenberger L.E.
        • Lee H.J.
        • Lee J.K.
        • Grace K.A.
        Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.
        Circulation. 2004; 110: 3512-3517
        • Brown B.G.
        • Zhao X.Q.
        • Chait A.
        • et al.
        Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
        N. Engl J Med. 2001; 345: 1583-1592
        • Ballantyne C.M.
        • Davidson M.H.
        • McKenney J.
        • Keller L.H.
        • Bajorunas D.R.
        • Karas R.H.
        Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
        Am J Cardiol. 2008; 101: 1428-1436
        • Sazonov V.
        • Maccubbin D.
        • Sisk C.M.
        • Canner P.L.
        Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose.
        Int J Clin Pract. 2013; 67: 297-302
        • Garg A.
        • Grundy S.M.
        Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus.
        JAMA. 1990; : 723-726
        • Elam M.B.
        • Hunninghake D.B.
        • Davis K.B.
        • et al.
        Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial disease multiple intervention trial.
        JAMA. 2000; : 1263-1270
        • Grundy S.M.
        • Vega G.L.
        • McGovern M.E.
        • et al.
        Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
        Arch Intern Med. 2002; : 1568-1576
        • Fazio S.
        • Guyton J.R.
        • Lin J.
        • Tomassini J.E.
        • Shah A.
        • Tershakovec A.M.
        Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome.
        Diabetes Obes Metabol. 2010; : 983-993
        • Hamilton S.J.
        • Chew G.T.
        • Davis T.M.
        • Watts G.F.
        Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients.
        Diabetes Vasc Dis Res. 2010; : 296-299
        • Sorrentino S.A.
        • Besler C.
        • Rohrer L.
        • et al.
        Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy.
        Circulation. 2010; : 110-122
        • Pang J.
        • Chan D.C.
        • Hamilton S.J.
        • Tenneti V.S.
        • Watts G.F.
        • Barrett P.H.R.
        Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
        Arterioscler Thromb Vasc Biol. 2014; 34: 427-432
        • Sahebkar A.
        Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
        Vasc Med. 2014; 19: 54-66
        • Bruckert E.
        • Labreuche J.
        • Amarenco P.
        Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis.
        Atherosclerosis. 2010; 210: 353-361
        • Lavigne P.M.
        • Karas R.H.
        The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression,.
        J Am Coll Cardiol. 2013; 61: 440-446
        • Higgins J.P.
        • Thompson S.G.
        • Deeks J.J.
        • Altman D.G.
        Measuring inconsistency in meta-analyses.
        BMJ. 2003; 327: 557-560
        • DerSimonian R.
        • Laird N.
        Meta-analysis in clinical trials.
        Control Clin Trials. 1986; 7: 177-188
        • Egger M.
        • Davey Smith G.
        • Schneider M.
        • Minder C.
        Bias in meta-analysis detected by a simple, graphical test.
        BMJ. 1997; 315: 629-634
        • Bodor E.T.
        • Offermanns S.
        Nicotinic acid: an old drug with a promising future.
        Br J Pharmacol. 2008; 153: S68-S75
        • Gille A.
        • Bodor E.T.
        • Ahmed K.
        • Offermanns S.
        Nicotinic acid: pharmacological effects and mechanisms of action.
        Annu Rev Pharmacol Toxicol. 2008; 48: 79-106
        • Lamon-Fava S.
        • Diffenderfer M.R.
        • Barrett P.H.
        • et al.
        Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.
        Arterioscler Thromb Vasc Biol. 2008; 28: 1672-1678
        • Hernandez C.
        • Molusky M.
        • Li Y.
        • Li S.
        • Lin J.D.
        Regulation of hepatic ApoC3 expression by PGC-1beta mediates hypolipidemic effect of nicotinic acid.
        Cell Metab. 2010; 12: 411-419
        • National Cholesterol Education Program Expert Panel on Detection
        E.; treatment of high blood cholesterol in, a. Third report of the national cholesterol Education Program (NCEP) Expert Panel on Detection, evaluation, and treatment of high blood cholesterol in Adults (Adult treatment Panel III) final report.
        Circulation. 2002; 106: 3143-3421
        • Genest J.
        • Frohlich J.
        • Fodor G.
        • McPherson R.
        Working Group on, H.; Other, D. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.
        CMAJ – Can Med Assoc J J de l'Association medicale Can. 2003; 169: 921-924
        • Birjmohun R.S.
        • Hutten B.A.
        • Kastelein J.J.
        • Stroes E.S.
        Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
        J Am Coll Cardiol. 2005; 45: 185-197
        • Chapman M.J.
        • Assmann G.
        • Fruchart J.C.
        • Shepherd J.
        • Sirtori C.
        European Consensus Panel on, H.-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid–a position paper developed by the European Consensus Panel on HDL-C.
        Curr Med Res Opin. 2004; 20: 1253-1268
        • Scanu A.M.
        • Bamba R.
        Niacin and lipoprotein (a): facts, uncertainties, and clinical considerations.
        Am J Cardiol. 2008; 101: S44-S47
        • Airan-Javia S.L.
        • Wolf R.L.
        • Wolfe M.L.
        • Tadesse M.
        • Mohler E.
        • Reilly M.P.
        Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low-and high-dose simvastatin monotherapy.
        Am Heart J. 2009; 157: 687e1-687e8
        • Bruckert E.
        • Hayem G.
        • Dejager S.
        • Yau C.
        • Begaud B.
        Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study.
        Cardiovasc Drugs Ther Spons by Int Soc Cardiovasc Pharmacother. 2005; 19: 403-414
        • Guyton J.R.
        • Bays H.E.
        Safety considerations with niacin therapy.
        Am J Cardiol. 2007; 99: 22C-31C
        • Canner P.L.
        • Furberg C.D.
        • McGovern M.E.
        Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project).
        Am J Cardiol. 2006; 97: 477-479